Opinion|Videos|March 20, 2025
Other Investigational Drug Delivery Systems in NMIBC
Experts briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk non–muscle-invasive bladder cancer (NMIBC), and share their impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk NMIBC. What are your impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102?
Advertisement
Related to this article
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
Butterfly Medical has also submitted a premarket approval application to the FDA.
Advertisement
Advertisement
Trending on Urology Times
1
Urocross Expander System enters US commercial use for symptomatic BPH
2
Study assesses real-world outcomes with intranasal vardenafil for ED
3
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
4
Matching mCSPC treatment to the patient, not just the trial data
5